The availability of transgenic mice with fluorescently labeled L cells paves the way for a new wave of exploration into the mechanisms underlying GLP-1 and PYY release, with the potential to identify targets in L cells that could be exploited therapeutically for the treatment of diabetes and obesity. Here, GCG is linked to diabetes mellitus.